Cited by 142SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

Open access

Marion, Olivier, Del Bello, Arnaud, Abravanel, Florence, Couat, Chloé, Faguer, Stanislas, Esposito, Laure, Hebral, Anne Laure, Izopet, Jacques, Kamar, Nassim·2021·Annals of Internal Medicine

DOI 10.7326/m21-1341PMC PMC8252830

Open this paper in CoChat — free account

Abstract

Background: Recipients of solid organ transplant (SOT) are a high-risk group for severe SARS-CoV-2 infection. The mortality rate of patients with SOT during the COVID-19 pandemic has been reported to be approximately 20% (1). The anti–SARS-CoV-2 vaccines represent a hope to protect this population against this life-threatening infection.Objective: To assess the humoral response to messenger RNA (mRNA)–based vaccination in recipients of SOT.Methods: All patients with heart, kidney, liver, or pancreas transplants from the Midi-Pyrénées region (southwest France) are followed in our department. When the vaccination campaign started (7 January 2021), these patients were invited via text message, e-mail, or transplant patients' associations to be vaccinated. Patients were asked to register via a dedicated telephone number or website. They were vaccinated consecutively according to their registration date. According to the recommendations of the Francophone Society of Transplantation, anti–SARS-CoV-2 spike protein antibodies were monitored before and after vaccination. We used the SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay test (Beijing Wantai Biological Pharmacy Enterprise) (80% of patients) or another validated anti–SARS-CoV-2 spike protein assay. According to French law (loi Jardé), anonymous retrospective studies do not require institutional review board approval.Findings: By 16 April 2021, 950 patients of the 2666 from our cohort had received at least 1 dose of an mRNA vaccine (BNT162b2 vaccine [Pfizer-BioNTech], n = 942; mRNA-1273 vaccine [Moderna], n = 8) and had anti–SARS-CoV-2 antibodies monitored. Fifty patients had vaccination without monitoring of antibodies, 80 patients are planned to be vaccinated within the next month, and 257 patients declined the vaccine. We had no feedback from the remaining 1329 patients.

Integrity signals

Registry

Crossref · 10.7326/m21-1341

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
Boyarsky, B. J., Werbel, W. A., Avery, R. K., Tobian, A. A. R., Massie, A. B., Segev, D. L., & Garonzik‐Wang, J. (2021) · JAMA · doi:10.1001/jama.2021.4385 · Cited by 510
Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus
Grupper, A., Rabinowich, L., Schwartz, D., Schwartz, I. F., Ben‐Yehoyada, M., Shashar, M., Katchman, E. A., Halperin, T., Turner, D., Goykhman, Y., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16615 · Cited by 355
COVID-19 in solid organ transplant: A multi-center cohort study
Kates, O., Haydel, B., Florman, S., Rana, M., Chaudhry, Z., Ramesh, M., Safa, K., Kotton, C., Blumberg, E., Besharatian, B., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1097 · Cited by 351
Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients
Marinaki, S., Adamopoulos, S. N., Degiannis, D., Roussos, S., Pavlopoulou, I. D., Hatzakis, A. E., & Boletis, I. N. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16607 · Cited by 115

Flagged first, then by citations

Show all 5 references

Sorted by citations

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
Kamar, N., Abravanel, F., Marion, O., Couat, C., Izopet, J., & Bello, A. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108861 · Cited by 810
Self-citation
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
Sun, J., Zheng, Q., Madhira, V., Olex, A. L., Anzalone, A. J., Vinson, A. J., Singh, J. A., French, E., Abraham, A. G., Mathew, J., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7024 · Cited by 257
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Galmiche, S., Nguyen, L. B. L., Tartour, É., de Lamballerie, X. N., Wittkop, L., Loubet, P., & Launay, O. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.036 · Cited by 207
Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients
Bello, A. D., Abravanel, F., Marion, O., Couat, C., Esposito, L., Lavayssière, L., Izopet, J., & Kamar, N. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16775 · Cited by 128
Self-citation
Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD
Carr, E. J., Kronbichler, A., Graham-Brown, M. P. M., Abra, G. E., Argyropoulos, C., Harper, L., Lerma, E. V., Suri, R. S., Topf, J. M., Willicombe, M. K., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.027 · Cited by 113
Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant
Manothummetha, K., Chuleerarux, N., Sanguankeo, A., Kates, O. S., Hirankarn, N., Thongkam, A., Dioverti, M. V., Torvorapanit, P., Langsiri, N., Worasilchai, N., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.6822 · Cited by 111
COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study
Klugar, M., Riad, A., Mohanan, L., & Pokorná, A. (2021) · Vaccines · doi:10.3390/vaccines9121437 · Cited by 110
The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic
Nimmo, A., Gardiner, D. D., Ushiro‐Lumb, I., Ravanan, R., & Forsythe, J. L. R. (2022) · Transplantation · doi:10.1097/tp.0000000000004151 · Cited by 104
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients
Longlune, N., Nogier, M. B., Miédougé, M., Gabilan, C., Cartou, C., Seigneuric, B., Bello, A. D., Marion, O., Faguer, S., Izopet, J., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab193 · Cited by 96
Self-citation
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Marjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84
Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis
Liu, C., Lee, J., Ta, C., Soroush, A., Rogers, J. R., Kim, J. H., Natarajan, K., Zucker, J. E., Perl, Y., & Weng, C. (2022) · JMIR Public Health and Surveillance · doi:10.2196/35311 · Cited by 69
Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients
Prendecki, M. F., Thomson, T., Clarke, C., Martin, P., Gleeson, S., de Aguiar, R. C., Edwards, H., Mortimer, P. M., McIntyre, S., Mokreri, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02096-1 · Cited by 66
A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response
Masset, C., Kerleau, C., Garandeau, C., Ville, S., Cantarovich, D., Hourmant, M., Kervella, D., Houzet, A., Guillot-Gueguen, C., Guihard, I., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.08.017 · Cited by 59
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy
Tamari, R., Politikos, I., Knorr, D. A., Vardhana, S. A., Young, J. C., Marcello, L. T., Doddi, S., Devlin, S. M., Ramanathan, L. V., Pessin, M. S., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0142 · Cited by 58
COVID-19 Vaccination in Patients with Heart Failure: A Position Paper of the Heart Failure Association of the European Society of Cardiology
Rosano, G. M. C., Jankowska, E. A., Ray, R., Metra, M., Abdelhamid, M., Adamopoulos, S. N., Anker, S. D., Bayés‐Genís, A., Belenkov, Y. N., Gal, T. B., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2356 · Cited by 59
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
Thomas, S. J., Perez, J. L., Lockhart, S. P., Hariharan, S., Kitchin, N. R. E., Bailey, R. E., Liau, K., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.046 · Cited by 57
Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis
Chen, X., Luo, D., Mei, B., Du, J., Liu, X., Xie, H., Liu, L., Su, S., & Mai, G. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.12.004 · Cited by 57
Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
Dietz, L. L., Juhl, A. K., Søgaard, O. S., Reekie, J., Nielsen, H., Johansen, I. S., Benfield, T., Wiese, L., Stærke, N. B., Jensen, T. Ø., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00277-x · Cited by 55
COVID-19 Disease Severity Among People With HIV Infection or Solid Organ Transplant in the United States: A Nationally-Representative, Multicenter, Observational Cohort StudyPreprint
Sun, J., Patel, R. C., Zheng, Q., Madhira, V., Olex, A. L., Islam, J. Y., French, E., Chiang, T. P., Akselrod, H., Moffitt, R. A., et al. (2021) · SSRN Electronic Journal · doi:10.1101/2021.07.26.21261028 · Cited by 51
Coordinated cellular and humoral immune responses after two‐dose SARS‐CoV2 mRNA vaccination in liver transplant recipients
D’Offizi, G., Agrati, C., Comandini, U. V., Castilletti, C., Puro, V., Piccolo, P., Montalbano, M., Meschi, S., Tartaglia, E., Sorace, C., et al. (2021) · Liver International · doi:10.1111/liv.15089 · Cited by 42
Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls
Hamm, S. R., Møller, D. L., Pérez‐Alós, L., Hansen, C. B., Pries‐Heje, M. M., Heftdal, L. D., Hasselbalch, R. B., Fogh, K., Madsen, J. R., Armenteros, J. J. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832501 · Cited by 43
Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis
Efros, O., Anteby, R., Halfon, M., Meisel, E., Klang, E., & Soffer, S. (2022) · Vaccines · doi:10.3390/vaccines10010095 · Cited by 40
Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients
Kamar, N., Abravanel, F., Marion, O., Esposito, L., Hébral, A. L., Médrano, C., Guitard, J., Lavayssière, L., Cointault, O., Nogier, M. B., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.16950 · Cited by 40
Self-citation
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
Cheung, K. S., Mok, C. H., Mao, X., Zhang, R., Hung, I. F., Seto, W., & Yuen, M. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0087 · Cited by 40
mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients
Kwon, J. H., Tenforde, M. W., Gaglani, M., Talbot, H. K., Ginde, A. A., McNeal, T., Ghamande, S. A., Douin, D. J., Casey, J. D., Mohr, N. M., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac118 · Cited by 38
The risk and consequences of breakthrough SARS-CoV-2 infection in solid organ transplant recipients relative to non-immunosuppressed controls
Vinson, A. J., Anzalone, A. J., Sun, J., Dai, R., Agarwal, G., Lee, S. B., French, E., Olex, A. L., Ison, M. G., & Mannon, R. B. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17117 · Cited by 37
Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients
Timmermann, L., Globke, B., Lurje, G., Schmelzle, M., Schöning, W., Öllinger, R., Pratschke, J., Eberspächer, B., Drosten, C., Hofmann, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9121422 · Cited by 35
Reduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in Chile
Balcells, M. E., Corre, N. L., Durán, J., Ceballos, M. E., Vizcaya, C., Mondaca, S., Dib, M., Ricardo Rabagliati, B., Mauricio Sarmiento, M., Burgos, P. I., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac167 · Cited by 36
Humoral and cellular response of COVID‐19 vaccine among solid organ transplant recipients: A systematic review and meta‐analysis
Meshram, H. S., Kute, V., Rane, H., Dave, R., Banerjee, S., Mishra, V. V., & Chauhan, S. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13926 · Cited by 33
Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis
Mingyao, B., Tam, A. R., Chan, K. W., Ma, M. K. M., Hung, I. F., Yap, D. Y. H., & Chan, T. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.827859 · Cited by 31
Antibody response to two doses of inactivated SARS‐CoV‐2 vaccine (CoronaVac) in kidney transplant recipients
Sadioğlu, R. E., Demir, E., Evren, E., Aktar, M., Şafak, S., Artan, A. S., Meşe, S., Ağaçfidan, A., Çınar, G., Önel, M., et al. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13740 · Cited by 30
Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV ‐2 vaccine in liver transplant recipients
Meunier, L., Sanavio, M., Dumortier, J., Meszaros, M., Faure, S., Bedoya, J. U., Echenne, M., Boillot, O., Debourdeau, A., & Pageaux, G. (2022) · Liver International · doi:10.1111/liv.15258 · Cited by 29
Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients
Marion, O., Bello, A. D., Abravanel, F., Faguer, S., Esposito, L., Hebral, A. L., Bellière, J., Izopet, J., & Kamar, N. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001248 · Cited by 29
Self-citation
SARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)
Bruminhent, J., Setthaudom, C., Chaumdee, P., Boongird, S., Kiertiburanakul, S., Malathum, K., Nongnuch, A., Phuphuakrat, A., Jirasiritham, S., Janphram, C., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16867 · Cited by 28
Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine
Charmetant, X., Espi, M., Barba, T., Ovize, A., Morélon, E., Mathieu, C., & Thaunat, O. (2022) · American Journal of Transplantation · doi:10.1111/ajt.16990 · Cited by 25
Immunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipients
Bruminhent, J., Setthaudom, C., Kitpermkiat, R., Kiertiburanakul, S., Malathum, K., Assanatham, M., Nongnuch, A., Phuphuakrat, A., Chaumdee, P., Janphram, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07574-w · Cited by 25
Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine
Saharia, K., Husson, J. S., Niederhaus, S. V., Iraguha, T., Avila, S. V., Yoo, Y. J., Hardy, N. M., Fan, X., Omili, D. O., Crane, A., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1391 · Cited by 26
SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study
Dib, M., Corre, N. L., Ortiz, C., García, D., Marcela Ferrés, G., Martínez-Valdebenito, C., Ruiz-Tagle, C., Ojeda, M. J., Espinoza, M., Jara, A., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100371 · Cited by 25
Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results
Medina-Pestana, J., Covas, D. T., Viana, L. A., Dreige, Y. C., Nakamura, M. R., Lucena, E. F., Requião-Moura, L. R., Fortaleza, C. M. C. B., Foresto, R. D., Junior, H. T. S., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000004036 · Cited by 24
The Case for Mandating COVID-19 Vaccines for Health Care Workers
Klompas, M., Pearson, M. M., & Morris, C. A. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2366 · Cited by 22
Immunogenicity of COVID ‐19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and meta‐analysis
Luo, D., Chen, X., Du, J., Mei, B., Wang, A., Kuang, F. L., Fang, C., Gan, Y., Peng, F., Yang, X., et al. (2022) · Liver International · doi:10.1111/liv.15403 · Cited by 22
COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness
Kherabi, Y., Launay, O., & Nguyen, L. B. L. (2022) · Viruses · doi:10.3390/v14102086 · Cited by 20
Universal Use of N95 Respirators in Healthcare Settings When Community Coronavirus Disease 2019 Rates Are High
Klompas, M., Rhee, C., & Baker, M. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab539 · Cited by 19
SARS-CoV-2 Vaccines: Safety and Immunogenicity in Solid Organ Transplant Recipients and Strategies for Improving Vaccine Responses
Grupper, A., & Katchman, H. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00359-0 · Cited by 17
Predictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Frölke, S. C., Bouwmans, P., Messchendorp, A. L., Geerlings, S. E., Hemmelder, M. H., Gansevoort, R. T., Hilbrands, L. B., Reinders, M. E. J., Sanders, J., Bemelman, F. J., et al. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001397 · Cited by 16
COVID-19 Vaccine Efficacy and Immunogenicity in End-Stage Renal Disease Patients and Kidney Transplant Recipients
Moreno, N. F., McAdams, R., Goss, J. A., & Galván, N. T. N. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00366-1 · Cited by 18
Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients
Ferreira, V. H., Marinelli, T. M., Ierullo, M., Ku, T., Hall, V. G., Majchrzak-Kita, B., Kulasingam, V., Humar, A., & Kumar, D. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab542 · Cited by 18
Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis
Verleye, A., Wijtvliet, V. P. W. M., Abrams, S., Hellemans, R., Bougrea, R., Massart, A., Pipeleers, L., Wissing, K. M., Ariën, K. K., Winter, B. Y. D., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac174 · Cited by 17
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
Lake, D. F., Roeder, A. J., González‐Moa, M. J., Koehler, M. A., Kaleta, E. J., Jasbi, P., Vanderhoof, J., McKechnie, D., Forman, J., Edwards, B. A., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00151-2 · Cited by 16
Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes
Zhou, X., Lu, H., Sang, M., Qiu, S., Yuan, Y., Wu, T., Chen, J., & Sun, Z. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2184754 · Cited by 16
Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccinesPreprint
Prendecki, M. F., Thomson, T., Clarke, C., Martin, P., Gleeson, S., de Aguiar, R. C., Edwards, H., Mortimer, P. M., McIntyre, S., Lewis, S., et al. (2021) · medRxiv · doi:10.1101/2021.07.09.21260192 · Cited by 14
Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies
Figueiredo, J. C., Hirsch, F. R., Kushi, L. H., Nembhard, W. N., Crawford, J. M., Mantis, N. J., Finster, L. J., Merin, N. M., Merchant, A. A., Reckamp, K. L., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac171 · Cited by 14
Humoral response to SARS-CoV-2 is well preserved and symptom dependent in kidney transplant recipients
Magicová, M., Fialová, M., Zahrádka, I., Bloudíčková, S. R., Hačkajlo, D., Raška, P., Střı́ž, I., & Viklický, O. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16746 · Cited by 15
Head-to-Head Comparison of Response Rates to the Two mRNA SARS-CοV-2 Vaccines in a Large Cohort of Solid Organ Transplant (SOT) Recipients
Marinaki, S., Degiannis, D., Roussos, S., Xagas, E., Tsoutsoura, P., Adamopoulos, S. N., Sypsa, V., Chaidaroglou, A. S., Pavlopoulou, I. D., Hatzakis, A. E., et al. (2022) · Vaccines · doi:10.3390/vaccines10020190 · Cited by 13
Association Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients
Zahrádka, I., Petr, V., Módos, I., Magicová, M., Dušek, L., & Viklický, O. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2973 · Cited by 13
Immunogenicity of the ChAdOx1 nCoV-19 and the BBV152 Vaccines in Patients with Autoimmune Rheumatic DiseasesPreprint
Shenoy, P. D., Ahmed, S., Cherian, S., Paul, A., Shenoy, V., Vijayan, A., Reji, R., Thambi, A., As, S. B., & Mohan, M. (2021) · medRxiv · doi:10.1101/2021.06.06.21258417 · Cited by 13
COVID-19 in liver transplant recipients
Piedade, J., & Pereira, G. (2021) · Journal of Liver Transplantation · doi:10.1016/j.liver.2021.100026 · Cited by 12
Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy
Podrazil, M., Táborská, P., Stakheev, D., Rataj, M., Lašťovička, J., Vlachova, A., Pohunek, P., Bartůňková, J., & Smrž, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892277 · Cited by 13
Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022
Downes, K. J., Statler, V. A., Orscheln, R. C., Cousino, M. K., Green, M., Michaels, M. G., Muller, W. J., Sharma, T. S., Danziger‐Isakov, L. A., & Ardura, M. I. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab098 · Cited by 11
Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine
Abravanel, F., Marion, O., Bello, A. D., Beunon, T., Romieu, R., Couat, C., Pucelle, M., Staes, L., Guitard, J., Esposito, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10030354 · Cited by 11
Self-citation
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study
Biscarini, S., Villa, S., Genovese, C., Tomasello, M., Tonizzo, A., Fava, M., Iannotti, N., Bolis, M., Mariani, B., Valzano, A. G., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10082002 · Cited by 11
Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation
Lucca, F., Bezzerri, V., Danese, E., Olioso, D., Peserico, D., Boni, C., Cucchetto, G., Montagnana, M., Tridello, G., Meneghelli, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020908 · Cited by 11
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
Asdaq, S. M. B., Jomah, S., Rabbani, S. I., Alamri, A. M., Alshammari, S. K. S., Duwaidi, B. S., Al-Shammari, M., Alamri, A. S., Alsanie, W. F., Alhomrani, M., et al. (2022) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2022/6913772 · Cited by 12
Robust spike-specific CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study
Federico, L., Tvedt, T. H. A., Gainullin, M., Osen, J. R., Chaban, V., Lund, K. P., Tietze, L., Tran, T. T., Lund‐Johansen, F., Kared, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210899 · Cited by 11
Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings
Panahi, Y., Einollahi, B., Beiraghdar, F., Darvishi, M., Fathi, S., Javanbakht, M., Shafiee, S., & Akhavan‐Sigari, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947602 · Cited by 10
Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection
Miele, M., Busà, R., Russelli, G., Sorrentino, M. C., Bella, M. D., Timoneri, F., Vitale, G., Calzolari, E., Vitulo, P., Mularoni, A., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10081563 · Cited by 9
Delayed and Attenuated Antibody Responses to Coronavirus Disease 2019 Vaccination With Poor Cross-Variant Neutralization in Solid-Organ Transplant Recipients—A Prospective Longitudinal Study
Liew, M. Y., Mathews, J., Li, A., Singh, R., Jaramillo, S. A., Weiss, Z., Bowman, K. A., Ankomah, P., Ghantous, F., Lewis, G. D., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad369 · Cited by 8
Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients – a case series with four patients
Schneider, J., Wobser, R., Kühn, W., Wagner, D., Tanriver, Y., & Walz, G. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03154-w · Cited by 9
Vaccine serologic responses among transplant patients associate with COVID-19 infection and T peripheral helper cellsPreprint
Lemieux, J. E., Li, A., Gentili, M., Perugino, C. A., Weiss, Z., Bowman, K. A., Ankomah, P., Liu, H., Lewis, G. D., Bitar, N., et al. (2021) · medRxiv · doi:10.1101/2021.07.11.21260338 · Cited by 8
Humoral Immune Response to COVID-19 Vaccination in Hemodialysis Patients: A Retrospective, Observational Case–Control Pilot Study
Piscitani, L., Pinto, R. D., Basili, A., Tunno, M., & Ferri, C. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-021-00502-5 · Cited by 7
SARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gaps
Sigler, R., & Aslam, S. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13809 · Cited by 7
Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients
Messchendorp, A. L., Sanders, J., Abrahams, A. C., Bemelman, F. J., Bouwmans, P., van den Dorpel, R. M. A., Hilbrands, L. B., Imhof, C., Reinders, M. E. J., Rispens, T., et al. (2024) · Viruses · doi:10.3390/v16010114 · Cited by 7
Matched Versus Mixed COVID-19 Vaccinations in Korean Solid Organ Transplant Recipients: An Observational Study
Kang, J., Lee, J., Huh, K. H., Joo, D. J., Lee, J. G., Kim, H. R., Kim, H. Y., Lee, M., Jung, I., Kim, M. Y., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004241 · Cited by 7
Anti–SARS-CoV-2 spike protein S1 receptor-binding domain antibody after vaccination with inactivated whole-virus SARS-CoV-2 in end-stage kidney disease patients: an initial report
Bruminhent, J., Boongird, S., Assanatham, M., Kiertiburanakul, S., Malathum, K., Nongnuch, A., Phuphuakrat, A., Chaumdee, P., Jirasiritham, S., Janphram, C., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.08.007 · Cited by 7
Coronavirus disease 2019 and the liver
Esteban, J. P., Sobotka, L., & Rockey, D. C. (2022) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000826 · Cited by 6
Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study
Benotmane, I., Gautier-Vargas, G., Cognard, N., Olagne, J., Heibel, F., Braun-Parvez, L., Martzloff, J., Perrin, P., Pszczolinski, R., Moulin, B., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071107 · Cited by 6
Immunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third dose
Margioris, A. N. (2022) · HORMONES · doi:10.1007/s42000-022-00365-y · Cited by 6
Integrated cell-free DNA and cytokine analysis uncovers distinct tissue injury and immune response patterns in solid organ transplant recipients with COVID-19Preprint
Andargie, T. E., Zhou, W., Karaba, A. H., Li, T., Seifuddin, F., Rittenhouse, A. G., Kong, H., Singh, K., Woodward, R. N., Iacono, A. T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1262270/v1 · Cited by 6
COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management
Perreault, G., Ching, C. K., & Nobel, Y. R. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231188586 · Cited by 5
Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients
Sigler, R., Chen, V., & Law, N. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00368-z · Cited by 4
Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study
Wasserbauer, M., Hlava, Š., Trojánek, M., Šťovíček, J., Milota, T., Drábek, J., Koptová, P., Cupkova, A., Pichlerová, D., Frýbová, B., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273612 · Cited by 5
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome
HELFGOTT, D. C., Racine‐Brzostek, S., Short, K. J., Zhao, Z., Christos, P. J., Nino, I., Niu, T., Contreras, J., Ritchie, E. K., Desai, P. M., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2131414 · Cited by 5
Sars‐Cov ‐2 vaccination in liver transplant recipients: The ‘holy grail’ in a hostile environment
Burra, P., & Russo, F. P. (2022) · Liver International · doi:10.1111/liv.15226 · Cited by 5
Reply to: “Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!”
Rabinowich, L., Shibolet, O., & Katchman, H. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.037 · Cited by 5
Effect of age and rural residency on perceptions about SARS‐CoV‐2 pandemic and vaccination in kidney transplant recipients
Singh, G., DeWalle, J., Tanrıöver, B., Singh, N. K., Chang, A. R., & Anand, P. M. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13943 · Cited by 4
Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation
Donadeu, L., Gómez‐Ollés, S., Casanova‐Ferrer, F., Torija, A., López‐Meseguer, M., Boada-Pérez, M., Kervella, D., Crespo, E., Carrera, C., Campos‐Varela, I., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1463769 · Cited by 4
COVID‐19 Vaccine Response in Pediatric Oncology Patients
Kam, B. N., Wang, Y., Qin, F., Long, A. H., Klein, O. R., & Aftandilian, C. C. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31572 · Cited by 4
Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19
Wieland, E. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000945 · Cited by 4
Infectious complications and vaccines
Ljungman, P. T. (2021) · Hematology · doi:10.1182/hematology.2021000294 · Cited by 4
A Retrospective Cross-Sectional Study of Severe Breakthrough SARS-CoV-2 Infection in the General Population Requiring Hospitalization Within a Single Health System
Acharya, R., Kafle, S., KANDINATA, N. N., Slipman, B., Ghimire, M., & Trotter, A. B. (2022) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4662 · Cited by 4
Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients
Pinchera, B., Rosa, C., Moriello, N. S., Salemi, F., Amerigo, P., Zumbo, G., Scotto, R., Villari, R., Paolo, R., Spirito, L., et al. (2022) · Viruses · doi:10.3390/v14091951 · Cited by 4
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Bouza, E., Martı́n, M., Alés, J. E., Aragonés, N., Barragán, B., de la Cámara, R., del Pozo, J. L., García‐Gutiérrez, V., García‐Sánz, R., Gracia, D., et al. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/087.2022 · Cited by 6
Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation Because of Hepatocellular Carcinoma
Akbulut, S., BAĞCI, N., Akyuz, M., Garzali, I. U., Sarıtaş, H., Tamer, M., İnce, V., Ünsal, S., Aloun, A., & Yılmaz, S. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.01.038 · Cited by 4
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients
Rendina, M. G., Barone, M., Lillo, C., Trapani, S., Masiero, L., Trerotoli, P., Puoti, F., Lupo, L., Tandoi, F., Agnes, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203854 · Cited by 4
Clinical application of COVID-19 vaccine in liver transplant recipients
Liu, F. C., Xie, M., & Rao, W. H. (2023) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2023.08.010 · Cited by 4
Evaluation of Humoral Response following SARS-CoV-2 mRNA-Based Vaccination in Liver Transplant Recipients Receiving Tailored Immunosuppressive Therapy
Manzia, T. M., Sensi, B., Conte, L. E., Siragusa, L., Angelico, R., Frongillo, F., & Tisone, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216913 · Cited by 4
Measures to Increase Immunogenicity of SARS-CoV-2 Vaccines in Solid Organ Transplant Recipients: A Narrative Review
Yu, B., Tamargo, C. L., Brennan, D. C., & Kant, S. (2023) · Vaccines · doi:10.3390/vaccines11121755 · Cited by 4
Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection
Pasikhova, Y., Morrison, A. R., Katzman, J. H., & Syed, M. (2022) · Cancer Control · doi:10.1177/10732748211070720 · Cited by 4
Humoral Response of Patients With Autoimmune Rheumatic Disease to BNT162b2 Vaccine: A Retrospective Comparative Study
Alsaed, O. S., Emadi, S. A., Satti, E., Muthanna, B., Veettil, S. F. A., Ashour, H., Chandra, P., Al‐Kuwari, E., & Coyle, P. V. (2022) · Cureus · doi:10.7759/cureus.24585 · Cited by 4

Authors: Marion, O., Del Bello, A., Abravanel, F., Couat, C., Faguer, S., Esposito, L., Hebral, A. L., Izopet, J., & Kamar, N.
Affiliations: Université Toulouse III - Paul Sabatier (FR)
Toulouse Rangueil University Hospital and Paul Sabatier University, Toulouse, France
Hôpital Rangueil (FR)
Toulouse Rangueil University Hospital, Toulouse, France
ORCID: Marion, Olivier
Del Bello, Arnaud
Abravanel, Florence
Faguer, Stanislas
Izopet, Jacques
Kamar, Nassim
Venue: Annals of Internal Medicine
Publisher: American College of Physicians
Published: 2021-09
Volume: 174
Issue: 9
Pages: 1336-1338
ISSN: 0003-4819 (ISSN-L)
1539-3704
DOI: 10.7326/m21-1341
PMC: PMC8252830
OpenAlex: W3164162028
Cited by: 142
References: 5
Citations by year: 2026: 2 · 2025: 6 · 2024: 12 · 2023: 22 · 2022: 63 · 2021: 37
FWCI: 10.61
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations: Annals of Internal Medicine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Social Sciences › Health › Vaccine Coverage and Hesitancy
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, COVID-19 vaccines, mRNA vaccines, solid organ transplant recipients, vaccine safety, immunogenicity, immunosuppression
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Viral, Female, Humans, Male, Middle Aged, Immunocompromised Host, Transplant Recipients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks